HGF/MET and the Immune System: Relevance for Cancer Immunotherapy.
Int J Mol Sci
; 19(11)2018 Nov 14.
Article
em En
| MEDLINE
| ID: mdl-30441809
ABSTRACT
An overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) axis promotes tumorigenesis and tumor progression in various cancer types. Research data recently evidenced that HGF/MET signaling is also involved also in the immune response, mainly modulating dendritic cells functions. In general, the pathway seems to play an immunosuppressive role, thus hypothesizing that it could constitute a mechanism of primary and acquired resistance to cancer immunotherapy. Recently, some approaches are being developed, including drug design and cell therapy to combine MET and programmed cell death receptor-1 (PD-1)/programmed cell death receptor-ligand 1 (PD-L1) inhibition. This approach could represent a new weapon in cancer therapy in the future.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fator de Crescimento de Hepatócito
/
Proteínas Proto-Oncogênicas c-met
/
Imunoterapia
/
Neoplasias
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Itália